BCL2 accelerates inflammation-induced BALB/c plasmacytomas and promotes novel tumors with coexisting T(12;15) and T(6;15) translocations - PubMed (original) (raw)

. 2003 Dec 15;63(24):8656-63.

Affiliations

PMID: 14695177

BCL2 accelerates inflammation-induced BALB/c plasmacytomas and promotes novel tumors with coexisting T(12;15) and T(6;15) translocations

Santiago Silva et al. Cancer Res. 2003.

Abstract

Previous studies on peritoneal plasmacytomas (PCTs) in BALB/c (C) mice suggested that the enforced expression of the death repressor BCL2 in B cells might facilitate the malignant transformation of aberrant B cells containing Myc-activating T(12;15) translocations, generating an improved model of plasmacytomagenesis. To investigate this hypothesis, we backcrossed a human BCL2 transgene onto strain C and performed a PCT induction study with pristane in the newly generated C.BCL2 congenics. In specific pathogen-free-maintained C.BCL2 mice, PCT incidence (19 of 34, 56%) was 24 times higher than in specific pathogen-free-maintained C mice (1 of 44, 2.3%), and tumor onset (113 days) was half that of conventionally maintained C mice (220 days). BCL2 transgenic PCT harbored T(12;15) translocations (12 of 12 tumors) with an unusual clustering of translocation breakpoints in the near 5' flank of Myc (4 of 5 tumors, 80%). Five tumors contained coexisting T(12;15) and T(6;15) translocations (not observed in >300 karyotyped PCTs from conventionally maintained C mice). BCL2 transgenic C57BL/6 mice exclusively developed B lymphomas (11 of 20, 55%) that also contained T(12;15) translocations (11 of 11 cases) with breakpoints in the near 5' flank of Myc (five of five tumors). We conclude that BCL2 accelerates PCT with novel Myc-activating translocations independently of environmental antigen stimulation. Accelerated plasmacytomagenesis in strain C.BCL2 may be useful for designing and testing BCL2 inhibition strategies in human plasma cell tumors overexpressing BCL2, such as Waldenström's macroglobulinemia and multiple myeloma.

PubMed Disclaimer

Cited by

Waldenström macroglobulinemia: clinical and immunological aspects, natural history, cell of origin, and emerging mouse models.
Janz S. Janz S. ISRN Hematol. 2013 Sep 9;2013:815325. doi: 10.1155/2013/815325. ISRN Hematol. 2013. PMID: 24106612 Free PMC article. Review.
Distinct granuloma responses in C57BL/6J and BALB/cByJ mice in response to pristane.
Chen H, Liao D, Cain D, McLeod I, Ueda Y, Guan Z, Raetz C, Kelsoe G. Chen H, et al. Int J Exp Pathol. 2010 Oct;91(5):460-71. doi: 10.1111/j.1365-2613.2010.00725.x. Int J Exp Pathol. 2010. PMID: 20681981 Free PMC article.
IL-6 and MYC collaborate in plasma cell tumor formation in mice.
Rutsch S, Neppalli VT, Shin DM, DuBois W, Morse HC 3rd, Goldschmidt H, Janz S. Rutsch S, et al. Blood. 2010 Mar 4;115(9):1746-54. doi: 10.1182/blood-2009-08-237941. Epub 2009 Dec 17. Blood. 2010. PMID: 20018915 Free PMC article.
AID-deficient Bcl-xL transgenic mice develop delayed atypical plasma cell tumors with unusual Ig/Myc chromosomal rearrangements.
Kovalchuk AL, duBois W, Mushinski E, McNeil NE, Hirt C, Qi CF, Li Z, Janz S, Honjo T, Muramatsu M, Ried T, Behrens T, Potter M. Kovalchuk AL, et al. J Exp Med. 2007 Nov 26;204(12):2989-3001. doi: 10.1084/jem.20070882. Epub 2007 Nov 6. J Exp Med. 2007. PMID: 17998390 Free PMC article.
Transgenic mouse model of IgM+ lymphoproliferative disease mimicking Waldenström macroglobulinemia.
Tompkins VS, Sompallae R, Rosean TR, Walsh S, Acevedo M, Kovalchuk AL, Han SS, Jing X, Holman C, Rehg JE, Herms S, Sunderland JS, Morse HC, Janz S. Tompkins VS, et al. Blood Cancer J. 2016 Nov 4;6(11):e488. doi: 10.1038/bcj.2016.95. Blood Cancer J. 2016. PMID: 27813533 Free PMC article.

BCL2 accelerates inflammation-induced BALB/c plasmacytomas and promotes novel tumors with coexisting T(12;15) and T(6;15) translocations - PubMed (original) (raw)